EU authorises intramuscular administration of Biogen’s Plegridy for MS
New administration option for relapsing-remitting MS patients
Read More
Tag: Plegridy
Price cuts secure NHS place for MS drugs
NICE is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis after price cuts enabled the cost regulator to endorse their routine use on the NHS.
Read More
NICE proposes restricting MS therapies
Novartis’ Extavia is the only beta interferon being endorsed by the National Institute for Health and Care Excellence as a cost-effective treatment option for multiple sclerosis.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
